ReviewFrontiers in immunology2025
Targeting toll-like receptors: unveiling potential therapeutic strategies for deep vein thrombosis.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Inflammation, Endothelial Dysfunction, and Platelet Dysregulation in Atrial Fibrillation with Chronic Kidney Disease: Toward a Biology-Informed Anticoagulation Strategy.Life (Basel, Switzerland) · 2026Review
- The role of ginkgo leaf extract and dipyridamole adjuvant treatment for reduction of lower limb deep vein thrombosis after proximal femoral nail antirotation surgery in elderly patients with intertrochanteric femoral fracture.Frontiers in pharmacology · 2026Article
- Pattern recognition receptor signaling in otitis media: immune crosstalk and pathogenic mechanisms.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Deep vein thrombosis (DVT) is a complex multifactorial vascular disease characterized by abnormal blood stasis and coagulation within the deep veins, primarily occurring in the lower limbs. This pathological condition not only causes local circulatory disruption but also has the potential to trigger life-threatening pulmonary embolism through thrombus detachment, thus posing a major threat to human health. Toll - like receptors (TLRs), essential components of the innate immune system, have been increasingly acknowledged as crucial determinants in the pathogenesis of DVT. TLRs possess the ability to recognize a diverse range of pathogen - associated molecular patterns (PAMPs) and endogenous danger - associated molecular patterns (DAMPs). Upon activation, they trigger a cascade of inflammatory responses that are intricately intertwined with the thrombotic process. This review comprehensively scrutinizes the extant knowledge pertaining to the role of TLRs in DVT. It systematically synthesizes the molecular mechanisms underpinning the participation of TLRs in DVT, spanning platelet activation, endothelial cell dysfunction, and leukocyte recruitment. Moreover, it delves profoundly into the potential of targeting TLRs as therapeutic strategies for DVT. This entails the exploration of the development and application of TLR inhibitors or antagonists. By elucidating these aspects, the objective is to proffer novel perspectives and insights for the prevention and treatment of DVT.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.